Business Description
Aridis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0403341045
Description
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | -1.81 | |||||
Debt-to-Equity | -0.41 | |||||
Debt-to-EBITDA | -8.43 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -40.73 | |||||
Beneish M-Score | 68.57 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.7 | |||||
3-Year EPS without NRI Growth Rate | 22.7 | |||||
3-Year FCF Growth Rate | -16.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.87 | |||||
9-Day RSI | 50.55 | |||||
14-Day RSI | 50.65 | |||||
6-1 Month Momentum % | -15.71 | |||||
12-1 Month Momentum % | -73.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.24 | |||||
Quick Ratio | 0.24 | |||||
Days Sales Outstanding | 10.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.7 | |||||
Shareholder Yield % | 83.35 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4.49 | |||||
Net Margin % | -5.81 | |||||
FCF Margin % | -91.28 | |||||
ROA % | -11.59 | |||||
ROIC % | -4.37 | |||||
ROC (Joel Greenblatt) % | -44.41 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.12 | |||||
EV-to-EBIT | -8.72 | |||||
EV-to-EBITDA | -13.42 | |||||
EV-to-Revenue | 0.39 | |||||
EV-to-Forward-Revenue | 1.05 | |||||
EV-to-FCF | -0.43 | |||||
Earnings Yield (Greenblatt) % | -11.47 | |||||
FCF Yield % | -619.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ARDS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aridis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 19.647 | ||
EPS (TTM) ($) | -0.162 | ||
Beta | 1.43 | ||
Volatility % | 52.63 | ||
14-Day RSI | 50.65 | ||
14-Day ATR ($) | 0.013512 | ||
20-Day SMA ($) | 0.065373 | ||
12-1 Month Momentum % | -73.78 | ||
52-Week Range ($) | 0.0312 - 0.4089 | ||
Shares Outstanding (Mil) | 44.57 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aridis Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aridis Pharmaceuticals Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Aridis Pharmaceuticals Inc Frequently Asked Questions
What is Aridis Pharmaceuticals Inc(ARDS)'s stock price today?
The current price of ARDS is $0.07. The 52 week high of ARDS is $0.41 and 52 week low is $0.03.
When is next earnings date of Aridis Pharmaceuticals Inc(ARDS)?
The next earnings date of Aridis Pharmaceuticals Inc(ARDS) is 2024-07-09 Est..
Does Aridis Pharmaceuticals Inc(ARDS) pay dividends? If so, how much?
Aridis Pharmaceuticals Inc(ARDS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |